Condition: Breast Cancer · Sponsor: Ain Shams University
The role of epigenetic regulators and their dysregulation in cancer have gained much attention recently, as they influence the gene expression of many oncogenes and tumor suppressor genes. Non-coding RNAs (ncRNAs) including (lncRNAs and miRNAs) and chromatin remodeling machinery proteins are key epigenetic regulators playing a key role in carcinogenesis. In addition, they can serve as diagnostic and prognostic markers in many cancer types including breast cancer. Therefore, studying these molecular markers will help in the diagnosis and prognosis as well as in the better understanding of this devastating disease.To the best of our knowledge, This is the first research work measuring the expression level of UPK1A-AS1 and/or UNC5B-AS1 in breast cancer clinical samples. These data could provide a promising approach in introducing a novel markers that help in the diagnosis and prognosis of breast cancer and provide a potential targets for gene therapy.
This description comes directly from the study's public registry record.
Sherihan Galal, phD · 01022850699 · Dr.sherehan@pharma.asu.edu.eg
Always discuss trial participation with your own doctor first.
| Faculty of pharmacy, Ain Shams University | Cairo, Egypt | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06759714